Phase II/II study of Adriamycin and Cisplatin versus Adriamycin for TC or DC resistant endometrial cancer
Phase 2
- Conditions
- recurrent endometrial cancer
- Registration Number
- JPRN-UMIN000009459
- Lead Sponsor
- Tokushima University hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Female
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Obvious infection, serous complication (heart disease, intestinal pneumonia, bleeding) edema greater than grade 2 neuropathy greater that\n grade 2 active other cancer symptomatic brain metastasis pleural effusion or ascites needed treatment pericardiac effusion
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method progression free survival
- Secondary Outcome Measures
Name Time Method overall survival, response rate, toxicity